Quantcast

Latest Lucentis Stories

2010-10-06 11:14:00

(Ivanhoe Newswire) "“ Age-related macular degeneration (AMD) is the leading cause of blindness for people over fifty. There are two treatments for AMD, although there is no cure, these treatments reduce the impact that macular degeneration has on vision. The two drugs include Bevacizumab (Avastin) and Ranibizumab (Lucentis). Scientists, for the first time, have discovered that there may not be any difference in the efficacy of these drugs- one is not better than the other. AMD affects...

2010-10-01 14:27:04

Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is believed to be the first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to...

2010-09-01 06:00:00

INCLINE VILLAGE, Nev., Sept. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the third quarter ended September 30, 2010 of approximately $86 million, as compared with actual results of $71.4 million for the third quarter of 2009, a 20 percent year-over-year increase. The growth is primarily driven by increased second quarter 2010 sales of Avastin®, Herceptin®, Lucentis® and...

2010-02-16 07:00:00

WALTHAM, Mass., Feb. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that both Genentech/Novartis Ophthalmics' Lucentis and Regeneron/Bayer's aflibercept will earn Decision Resources' proprietary clinical gold standard status for wet age-related macular degeneration in 2013 and 2018. A unique future gold standard cannot be identified because neither thought-leader opinion nor available clinical...

2009-12-09 06:00:00

VANCOUVER, Dec. 9 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland. EVEREST is the first multi-center, double-masked, indocyanine green angiography (ICG-A) -guided randomized controlled trial with an angiographic treatment outcome designed to assess the effect of Visudyne(R) (verteporfin photodynamic...

2009-10-10 07:50:30

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in the American Journal of Ophthalmology, is the first to report early outcomes of a prospective, double-masked, randomized, controlled trial...

2009-06-15 06:00:00

VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th Congress of the European Society of Ophthalmology in Amsterdam, the Netherlands. MONT BLANC is the European study of the Novartis sponsored SUMMIT clinical trial program which investigates the efficacy and safety of combining Visudyne(R) (Novartis Pharma AG)...

2009-06-02 06:00:00

VANCOUVER, June 2 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular degeneration ("wet AMD"). The purpose of the study is to determine if Visudyne combined with Lucentis reduces retreatment rates compared with Lucentis monotherapy, while maintaining similar vision...

2009-03-10 07:00:00

However, Off-Label Use of Avastin Will Take Market Share Away from Lucentis from 2012 to 2017, According to a New Report from Decision Resources WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that robust annual 17 percent growth in the age-related macular degeneration (AMD) market through 2012 will be driven primarily by expanding use of Genentech/Novartis Ophthalmics'...

2008-12-16 06:30:00

Mean visual acuity letter scores increased similarly in all treatment groups VANCOUVER, Dec. 16 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced six-month results from an interim analysis for the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions). The RADICAL study is a Phase II, multicenter, randomized, single-masked study comparing reduced-fluence Visudyne(R)-Lucentis(R) combination therapies (with or...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.